Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Zealand Pharma A/S is seeking a Senior Analytical Scientist to lead late-stage analytical development for peptide-based medicines. You will collaborate with CDMOs, drive validation and method transfer, and contribute to regulatory submissions in NDA/MAA processes.
Ideal candidates hold an MSc or PhD in a relevant field with several years in pharmaceutical analytical science or QC, and strong GMP/regulatory knowledge. The role emphasizes cross-functional teamwork and continuous learning.
Does it excite you to work with late-stage analytical development of innovative peptide-based medicines, and do you have experience in analytical science? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
You will play a key role in late-stage analytical development across Development and Life Cycle Management (LCM) projects. Close collaboration with Contract Development and Manufacturing Organizations (CDMOs) is central to the position, making effective coordination with external partners an important part of your day-to-day work.
We are looking for someone with an analytical mindset who takes ownership and communicates clearly across teams. You are a proactive problem-solver with a friendly approach, strong collaboration skills, and a genuine enjoyment of continuous learning.
You will join a highly experienced team in Analytical Development. We value a collaborative and supportive atmosphere in which great results are achieved together.
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation.
Join us and let's bond and be bold.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.
Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.
#LI-Onsite Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to be address a broad range of disease areas.
We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes.
In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease.
Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.